$TBPH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Theravance Biopharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Theravance Biopharma, Inc.. Get notifications about new insider transactions in Theravance Biopharma, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 24 2021 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 17.80 | 4,310 | 76,718 | 282,138 | 286.4 K to 282.1 K (-1.50 %) |
May 24 2021 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Business ... | Payment of Exercise | F | 17.80 | 3,779 | 67,266 | 437,341 | 441.1 K to 437.3 K (-0.86 %) |
Apr 29 2021 | TBPH | Theravance Biophar ... | PAKIANATHAN DEEPIKA | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | PAKIANATHAN DEEPIKA | Director | Grant | A | 0.00 | 9,828 | 0 | 17,895 | 8.1 K to 17.9 K (+121.83 %) |
Apr 29 2021 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Grant | A | 0.00 | 9,828 | 0 | 68,158 | 58.3 K to 68.2 K (+16.85 %) |
Apr 29 2021 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Grant | A | 0.00 | 9,828 | 0 | 9,828 | 0 to 9.8 K |
Apr 29 2021 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Grant | A | 0.00 | 9,828 | 0 | 44,034 | 34.2 K to 44 K (+28.73 %) |
Apr 29 2021 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Grant | A | 0.00 | 9,828 | 0 | 9,828 | 0 to 9.8 K |
Apr 29 2021 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Grant | A | 0.00 | 9,828 | 0 | 51,034 | 41.2 K to 51 K (+23.85 %) |
Apr 29 2021 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Grant | A | 0.00 | 9,828 | 0 | 81,605 | 71.8 K to 81.6 K (+13.69 %) |
Apr 29 2021 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Grant | A | 0.00 | 9,828 | 0 | 68,093 | 58.3 K to 68.1 K (+16.87 %) |
Apr 29 2021 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Grant | A | 0.00 | 9,828 | 0 | 51,034 | 41.2 K to 51 K (+23.85 %) |
Apr 29 2021 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Option Exercise | A | 20.35 | 6,000 | 122,100 | 6,000 | |
Apr 29 2021 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Grant | A | 0.00 | 9,828 | 0 | 34,810 | 25 K to 34.8 K (+39.34 %) |
Mar 11 2021 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Research & Tra ... | Sell | S | 20.00 | 8,829 | 176,580 | 343,679 | 352.5 K to 343.7 K (-2.50 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | GRAHAM RICHARD A | SVP, Development | Grant | A | 0.00 | 65,000 | 0 | 188,749 | 123.7 K to 188.7 K (+52.53 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Research & Tra ... | Grant | A | 0.00 | 65,000 | 0 | 384,395 | 319.4 K to 384.4 K (+20.35 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Grant | A | 0.00 | 170,000 | 0 | 1,445,169 | 1.3 M to 1.4 M (+13.33 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 316,916 | 251.9 K to 316.9 K (+25.80 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Grant | A | 0.00 | 65,000 | 0 | 258,044 | 193 K to 258 K (+33.67 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Grant | A | 0.00 | 65,000 | 0 | 400,280 | 335.3 K to 400.3 K (+19.39 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Business ... | Grant | A | 0.00 | 65,000 | 0 | 466,680 | 401.7 K to 466.7 K (+16.18 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 65,000 | 0 | 188,688 | 123.7 K to 188.7 K (+52.55 %) |
Feb 10 2021 | TBPH | Theravance Biophar ... | BRADY ANN | President, TBIL | Grant | A | 0.00 | 40,000 | 0 | 138,287 | 98.3 K to 138.3 K (+40.70 %) |
Dec 16 2020 | TBPH | Theravance Biophar ... | GRAHAM RICHARD A | SVP, Development | Sell | S | 19.47 | 7,500 | 146,058 | 123,749 | 131.2 K to 123.7 K (-5.71 %) |
Sep 03 2020 | TBPH | Theravance Biophar ... | GRAHAM RICHARD A | SVP, Development | Grant | A | 0.00 | 27,500 | 0 | 135,125 | 107.6 K to 135.1 K (+25.55 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Research & Tra ... | Payment of Exercise | F | 18.22 | 4,804 | 87,529 | 328,448 | 333.3 K to 328.4 K (-1.44 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Research & Tra ... | Sell | S | 18.00 | 17,103 | 307,854 | 333,252 | 350.4 K to 333.3 K (-4.88 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 18.22 | 13,946 | 254,096 | 1,289,115 | 1.3 M to 1.3 M (-1.07 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 18.22 | 4,804 | 87,529 | 256,723 | 261.5 K to 256.7 K (-1.84 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Payment of Exercise | F | 18.22 | 3,799 | 69,218 | 196,842 | 200.6 K to 196.8 K (-1.89 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 18.22 | 4,804 | 87,529 | 340,087 | 344.9 K to 340.1 K (-1.39 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 18.22 | 4,214 | 76,779 | 405,894 | 410.1 K to 405.9 K (-1.03 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Payment of Exercise | F | 18.22 | 4,323 | 78,765 | 123,135 | 127.5 K to 123.1 K (-3.39 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | Chief Medical Offic ... | Sell | S | 18.29 | 25,000 | 457,240 | 282,810 | 307.8 K to 282.8 K (-8.12 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | Chief Medical Offic ... | Payment of Exercise | F | 18.22 | 4,646 | 84,650 | 307,810 | 312.5 K to 307.8 K (-1.49 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | GRAHAM RICHARD A | SVP, Development | Payment of Exercise | F | 18.22 | 6,598 | 120,216 | 107,625 | 114.2 K to 107.6 K (-5.78 %) |
Aug 24 2020 | TBPH | Theravance Biophar ... | BRADY ANN | President, TBIL | Payment of Exercise | F | 18.22 | 2,292 | 41,760 | 100,579 | 102.9 K to 100.6 K (-2.23 %) |
Jul 29 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 20,000 | 0 | 127,458 | 107.5 K to 127.5 K (+18.61 %) |
Jul 06 2020 | TBPH | Theravance Biophar ... | PAKIANATHAN DEEPIKA | Director | Option Exercise | A | 20.66 | 5,000 | 103,300 | 5,000 | |
Jul 06 2020 | TBPH | Theravance Biophar ... | PAKIANATHAN DEEPIKA | Director | Option Exercise | A | 20.66 | 12,000 | 247,920 | 12,000 | |
Jul 06 2020 | TBPH | Theravance Biophar ... | PAKIANATHAN DEEPIKA | Director | Grant | A | 0.00 | 8,067 | 0 | 8,067 | 0 to 8.1 K |
May 22 2020 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Research & Tra ... | Payment of Exercise | F | 26.67 | 4,807 | 128,203 | 350,355 | 355.2 K to 350.4 K (-1.35 %) |
May 22 2020 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 26.67 | 13,946 | 371,940 | 1,303,061 | 1.3 M to 1.3 M (-1.06 %) |
May 22 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 26.67 | 4,807 | 128,203 | 261,527 | 266.3 K to 261.5 K (-1.80 %) |
May 22 2020 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Payment of Exercise | F | 26.67 | 3,801 | 101,373 | 200,641 | 204.4 K to 200.6 K (-1.86 %) |
May 22 2020 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 26.67 | 4,807 | 128,203 | 344,891 | 349.7 K to 344.9 K (-1.37 %) |
May 22 2020 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 26.67 | 4,214 | 112,387 | 410,108 | 414.3 K to 410.1 K (-1.02 %) |
May 22 2020 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 26.67 | 4,212 | 112,334 | 312,456 | 316.7 K to 312.5 K (-1.33 %) |
May 22 2020 | TBPH | Theravance Biophar ... | BRADY ANN | President, TBIL | Payment of Exercise | F | 26.67 | 2,292 | 61,128 | 102,871 | 105.2 K to 102.9 K (-2.18 %) |
Apr 30 2020 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Grant | A | 0.00 | 6,635 | 0 | 6,635 | 0 to 6.6 K |
Apr 30 2020 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Grant | A | 0.00 | 6,635 | 0 | 58,330 | 51.7 K to 58.3 K (+12.83 %) |
Apr 30 2020 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Grant | A | 0.00 | 6,635 | 0 | 34,206 | 27.6 K to 34.2 K (+24.07 %) |
Apr 30 2020 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Grant | A | 0.00 | 6,635 | 0 | 41,206 | 34.6 K to 41.2 K (+19.19 %) |
Apr 30 2020 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Grant | A | 0.00 | 6,635 | 0 | 71,777 | 65.1 K to 71.8 K (+10.19 %) |
Apr 30 2020 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Grant | A | 0.00 | 6,635 | 0 | 58,265 | 51.6 K to 58.3 K (+12.85 %) |
Apr 30 2020 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Grant | A | 0.00 | 6,635 | 0 | 41,206 | 34.6 K to 41.2 K (+19.19 %) |
Apr 30 2020 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Grant | A | 0.00 | 6,635 | 0 | 24,982 | 18.3 K to 25 K (+36.16 %) |
Apr 30 2020 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Option Exercise | A | 30.14 | 6,000 | 180,840 | 6,000 | |
Apr 30 2020 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Grant | A | 0.00 | 6,635 | 0 | 6,635 | 0 to 6.6 K |
Feb 24 2020 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Research & Tra ... | Payment of Exercise | F | 25.90 | 29,105 | 753,820 | 354,750 | 383.9 K to 354.8 K (-7.58 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 25.90 | 96,850 | 2,508,415 | 1,315,605 | 1.4 M to 1.3 M (-6.86 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 25.90 | 29,402 | 761,512 | 264,932 | 294.3 K to 264.9 K (-9.99 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Payment of Exercise | F | 25.90 | 7,213 | 186,817 | 203,040 | 210.3 K to 203 K (-3.43 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 25.90 | 29,136 | 754,622 | 349,698 | 378.8 K to 349.7 K (-7.69 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 25.90 | 24,392 | 631,753 | 412,920 | 437.3 K to 412.9 K (-5.58 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Payment of Exercise | F | 25.90 | 7,060 | 182,854 | 106,490 | 113.6 K to 106.5 K (-6.22 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 25.90 | 33,608 | 870,447 | 316,668 | 350.3 K to 316.7 K (-9.59 %) |
Feb 24 2020 | TBPH | Theravance Biophar ... | BRADY ANN | President, TBIL | Payment of Exercise | F | 25.90 | 5,948 | 154,053 | 105,163 | 111.1 K to 105.2 K (-5.35 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Research & Tra ... | Grant | A | 0.00 | 54,000 | 0 | 383,855 | 329.9 K to 383.9 K (+16.37 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Research & Tra ... | Grant | A | 0.00 | 65,000 | 0 | 329,855 | 264.9 K to 329.9 K (+24.54 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Grant | A | 0.00 | 168,000 | 0 | 1,412,455 | 1.2 M to 1.4 M (+13.50 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Grant | A | 0.00 | 170,000 | 0 | 1,244,455 | 1.1 M to 1.2 M (+15.82 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 54,000 | 0 | 294,334 | 240.3 K to 294.3 K (+22.47 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Grant | A | 0.00 | 65,000 | 0 | 240,334 | 175.3 K to 240.3 K (+37.07 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Grant | A | 0.00 | 65,000 | 0 | 210,253 | 145.3 K to 210.3 K (+44.75 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Grant | A | 0.00 | 54,000 | 0 | 378,834 | 324.8 K to 378.8 K (+16.62 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Grant | A | 0.00 | 65,000 | 0 | 324,834 | 259.8 K to 324.8 K (+25.02 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Grant | A | 0.00 | 54,000 | 0 | 437,312 | 383.3 K to 437.3 K (+14.09 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Grant | A | 0.00 | 65,000 | 0 | 383,312 | 318.3 K to 383.3 K (+20.42 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 20,000 | 0 | 113,550 | 93.6 K to 113.6 K (+21.38 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 43,550 | 0 | 93,550 | 50 K to 93.6 K (+87.10 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Grant | A | 0.00 | 54,000 | 0 | 350,276 | 296.3 K to 350.3 K (+18.23 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Grant | A | 0.00 | 65,000 | 0 | 296,276 | 231.3 K to 296.3 K (+28.10 %) |
Feb 05 2020 | TBPH | Theravance Biophar ... | BRADY ANN | President, TBIL | Grant | A | 0.00 | 40,000 | 0 | 111,111 | 71.1 K to 111.1 K (+56.25 %) |
Dec 16 2019 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Sell | S | 21.03 | 1,027 | 21,598 | 145,253 | 146.3 K to 145.3 K (-0.70 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 21.51 | 2,272 | 48,871 | 267,127 | 269.4 K to 267.1 K (-0.84 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 21.51 | 8,678 | 186,664 | 1,083,133 | 1.1 M to 1.1 M (-0.79 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 21.51 | 3,084 | 66,337 | 178,901 | 182 K to 178.9 K (-1.69 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Payment of Exercise | F | 21.51 | 1,472 | 31,663 | 147,753 | 149.2 K to 147.8 K (-0.99 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 21.51 | 2,272 | 48,871 | 262,106 | 264.4 K to 262.1 K (-0.86 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 21.51 | 2,335 | 50,226 | 320,759 | 323.1 K to 320.8 K (-0.72 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 21.51 | 2,272 | 48,871 | 259,900 | 262.2 K to 259.9 K (-0.87 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 21.51 | 2,710 | 58,292 | 233,968 | 236.7 K to 234 K (-1.15 %) |
Aug 22 2019 | TBPH | Theravance Biophar ... | BRADY ANN | President, TBIL | Payment of Exercise | F | 21.51 | 1,073 | 23,080 | 72,184 | 73.3 K to 72.2 K (-1.46 %) |
Jul 03 2019 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Option Exercise | A | 16.94 | 260,000 | 4,404,400 | 260,000 | |
Jul 03 2019 | TBPH | Theravance Biophar ... | Hindman Andrew A. | SVP, Chief Financia ... | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
May 22 2019 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 19.84 | 2,272 | 45,076 | 269,399 | 271.7 K to 269.4 K (-0.84 %) |
May 22 2019 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 19.84 | 8,678 | 172,172 | 1,091,811 | 1.1 M to 1.1 M (-0.79 %) |
May 22 2019 | TBPH | Theravance Biophar ... | Shafer Bradford J | EVP, Gen. Counsel, ... | Payment of Exercise | F | 19.84 | 2,488 | 49,362 | 181,985 | 184.5 K to 182 K (-1.35 %) |
May 22 2019 | TBPH | Theravance Biophar ... | SABESAN VIJAY | SVP, Technical Oper ... | Payment of Exercise | F | 19.84 | 1,474 | 29,244 | 149,225 | 150.7 K to 149.2 K (-0.98 %) |
May 22 2019 | TBPH | Theravance Biophar ... | PITZER KENNETH R | SVP, Prod Strat & C ... | Payment of Exercise | F | 19.84 | 2,272 | 45,076 | 264,378 | 266.7 K to 264.4 K (-0.85 %) |
May 22 2019 | TBPH | Theravance Biophar ... | PASQUALONE FRANK | SVP, Chief Comm Ops ... | Payment of Exercise | F | 19.84 | 1,604 | 31,823 | 323,094 | 324.7 K to 323.1 K (-0.49 %) |
May 22 2019 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Payment of Exercise | F | 19.84 | 2,272 | 45,076 | 262,172 | 264.4 K to 262.2 K (-0.86 %) |
May 22 2019 | TBPH | Theravance Biophar ... | HAUMANN BRETT K | SVP Clin Dev & Chie ... | Payment of Exercise | F | 19.84 | 2,705 | 53,667 | 236,678 | 239.4 K to 236.7 K (-1.13 %) |
May 22 2019 | TBPH | Theravance Biophar ... | BRADY ANN | President, TBIL | Payment of Exercise | F | 19.84 | 1,073 | 21,288 | 73,257 | 74.3 K to 73.3 K (-1.44 %) |
May 20 2019 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Sell | S | 20.19 | 2,673 | 53,968 | 27,571 | 30.2 K to 27.6 K (-8.84 %) |
May 20 2019 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Sell | S | 21.00 | 1,327 | 27,867 | 30,244 | 31.6 K to 30.2 K (-4.20 %) |
May 02 2019 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | Molineaux Susan | Director | Grant | A | 0.00 | 8,385 | 0 | 8,385 | 0 to 8.4 K |
May 02 2019 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | YOUNG WILLIAM D | Director | Grant | A | 0.00 | 8,385 | 0 | 51,695 | 43.3 K to 51.7 K (+19.36 %) |
May 02 2019 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Gift | G | 0.00 | 21,012 | 0 | 27,650 | 48.7 K to 27.7 K (-43.18 %) |
May 02 2019 | TBPH | Theravance Biophar ... | WHITESIDES GEORGE M | Director | Grant | A | 0.00 | 8,385 | 0 | 200,963 | 192.6 K to 201 K (+4.35 %) |
May 02 2019 | TBPH | Theravance Biophar ... | RINGROSE PETER S | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | RINGROSE PETER S | Director | Grant | A | 0.00 | 8,385 | 0 | 37,999 | 29.6 K to 38 K (+28.31 %) |
May 02 2019 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | O'Connor Donal | Director | Grant | A | 0.00 | 8,385 | 0 | 31,571 | 23.2 K to 31.6 K (+36.16 %) |
May 02 2019 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | MITCHELL DEAN J | Director | Grant | A | 0.00 | 8,385 | 0 | 34,571 | 26.2 K to 34.6 K (+32.02 %) |
May 02 2019 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | MALKIEL BURTON G | Director | Grant | A | 0.00 | 8,385 | 0 | 65,142 | 56.8 K to 65.1 K (+14.77 %) |
May 02 2019 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | Gunderson Robert V JR | Director | Grant | A | 0.00 | 8,385 | 0 | 51,630 | 43.2 K to 51.6 K (+19.39 %) |
May 02 2019 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | BROSHY ERAN | Director | Grant | A | 0.00 | 8,385 | 0 | 34,571 | 26.2 K to 34.6 K (+32.02 %) |
May 02 2019 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Option Exercise | A | 23.85 | 6,000 | 143,100 | 6,000 | |
May 02 2019 | TBPH | Theravance Biophar ... | Smaldone Alsup Laurie | Director | Grant | A | 0.00 | 8,385 | 0 | 18,347 | 10 K to 18.3 K (+84.17 %) |
Mar 06 2019 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Sell | S | 24.50 | 5,690 | 139,405 | 264,444 | 270.1 K to 264.4 K (-2.11 %) |
Mar 06 2019 | TBPH | Theravance Biophar ... | HEGDE SHARATHCHANDRA S | SVP, Research | Sell | S | 25.06 | 3,343 | 83,764 | 270,134 | 273.5 K to 270.1 K (-1.22 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | WORBOYS PHILIP D | SVP, Translational ... | Payment of Exercise | F | 27.00 | 3,986 | 107,622 | 270,644 | 274.6 K to 270.6 K (-1.45 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | Winningham Rick E | Chief Executive Off ... | Payment of Exercise | F | 27.00 | 13,477 | 363,879 | 1,099,462 | 1.1 M to 1.1 M (-1.21 %) |
Feb 22 2019 | TBPH | Theravance Biophar ... | SULIMAN SHEHNAAZ | SVP, Corp Dev & Str ... | Payment of Exercise | F | 27.00 | 5,763 | 155,601 | 97,198 | 103 K to 97.2 K (-5.60 %) |